BICALOX

This brand name is authorized in Australia, Hong Kong, New Zealand, Singapore, Tunisia, South Africa

Active ingredients

The drug BICALOX contains one active pharmaceutical ingredient (API):

1 Bicalutamide UNII A0Z3NAU9DP - BICALUTAMIDE

Bicalutamide is a non-steroidal antiandrogen, devoid of other endocrine activity. It binds to androgen receptors without activating gene expression, and thus inhibits the androgen stimulus. Regression of prostatic tumours results from this inhibition. Read about Bicalutamide

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
BICALOX Film-coated tablet	Medicines and Medical Devices Safety Authority (NZ)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L02BB03	Bicalutamide	L Antineoplastic and immunomodulating agents → L02 Endocrine therapy → L02B Hormone antagonists and related agents → L02BB Anti-androgens
Discover more medicines within L02BB03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: AU	Pharmaceutical Benefits Scheme	Identifier(s): 8094B
Country: HK	Department of Health Drug Office	Identifier(s): 59232
Country: NZ	Medicines and Medical Devices Safety Authority	Identifier(s): 12570
Country: SG	Health Sciences Authority	Identifier(s): 14145P
Country: TN	Direction de la Pharmacie et du Médicament	Identifier(s): 17083021
Country: ZA	Health Products Regulatory Authority	Identifier(s): 41/21.12/0818